Oncolytics Biotech EPS
The Earnings per Share (EPS) of Oncolytics Biotech (ONCY) as of Oct 12, 2026 is -0.41 USD. In the previous year, Earnings per Share (EPS) was -0.28 USD — a change of 48.08% (lower).
Get this data via API
Financial Data API
EPS
-0.41USD
YoY
48.08%
Last updated:
The Oncolytics Biotech EPS history
3 Years
10 Years
25 Years
Max
| YEAR | EPS | YoY |
|---|---|---|
| est | -0.10USD | -45.51% |
| est | -0.18USD | -1.81% |
| est | -0.18USD | -1.31% |
| est | -0.19USD | -22.08% |
| est | -0.24USD | -42.10% |
| -0.41USD | +48.08% | |
| -0.28USD | +5.28% | |
| -0.26USD | -9.80% | |
| -0.29USD | -12.81% | |
| -0.34USD | +2.13% | |
| -0.33USD | -63.10% | |
| -0.89USD | +37.36% | |
| -0.65USD | -11.35% | |
| -0.73USD | -12.07% | |
| -0.83USD | +7.54% | |
| -0.77USD | -37.92% | |
| -1.25USD | -32.33% | |
| -1.84USD | -39.39% | |
| -3.04USD | +17.05% | |
| -2.60USD | +36.45% | |
| -1.90USD | +3.40% | |
| -1.84USD | -31.01% | |
| -2.67USD | +5.37% | |
| -2.53USD | +1.57% | |
| -2.49USD | — |
Oncolytics Biotech Stock analysis
Frequently Asked Questions about Oncolytics Biotech stock
Earnings per Share (EPS) of Oncolytics Biotech is -0.41 USD in 2025.
Earnings per Share (EPS) of Oncolytics Biotech changed from -0.28 USD to -0.41 USD, representing a 48.08% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Oncolytics Biotech since 2006 – with annual values, charts, and detailed analysis.
Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.
EPS = Net Income / Shares Outstanding
Income Statement — Oncolytics Biotech
All Key Metrics — Oncolytics Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth